Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib.ACG Case Rep J. 2021 Nov; 8(11):e00690.AC
Abstract
Alopecia areata (AA) is a type of immune-mediated hair loss and is reported in patients with inflammatory bowel disease. This suggests that there might be a shared molecular pathway in the pathogenesis of AA and inflammatory bowel disease. In addition, tumor necrosis factor-alpha antagonists are also rarely associated with new-onset AA. We present a patient with Crohn's disease treated with adalimumab who developed AA that rapidly progressed to alopecia totalis and universalis. We describe the use of tofacitinib, a Janus kinase 1/3 inhibitor, to not only successfully treat the AA but also maintain her Crohn's disease.
Links
Pub Type(s)
Case Reports
Language
eng
PubMed ID
34840997
Citation
Akiyama, Shintaro, et al. "Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib." ACG Case Reports Journal, vol. 8, no. 11, 2021, pp. e00690.
Akiyama S, Lin A, Traboulsi C, et al. Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib. ACG Case Rep J. 2021;8(11):e00690.
Akiyama, S., Lin, A., Traboulsi, C., & Rubin, D. T. (2021). Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib. ACG Case Reports Journal, 8(11), e00690. https://doi.org/10.14309/crj.0000000000000690
Akiyama S, et al. Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib. ACG Case Rep J. 2021;8(11):e00690. PubMed PMID: 34840997.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib.
AU - Akiyama,Shintaro,
AU - Lin,Austin,
AU - Traboulsi,Cindy,
AU - Rubin,David T,
Y1 - 2021/11/24/
PY - 2020/12/21/received
PY - 2021/05/07/accepted
PY - 2021/11/29/entrez
PY - 2021/11/30/pubmed
PY - 2021/11/30/medline
SP - e00690
EP - e00690
JF - ACG case reports journal
JO - ACG Case Rep J
VL - 8
IS - 11
N2 - Alopecia areata (AA) is a type of immune-mediated hair loss and is reported in patients with inflammatory bowel disease. This suggests that there might be a shared molecular pathway in the pathogenesis of AA and inflammatory bowel disease. In addition, tumor necrosis factor-alpha antagonists are also rarely associated with new-onset AA. We present a patient with Crohn's disease treated with adalimumab who developed AA that rapidly progressed to alopecia totalis and universalis. We describe the use of tofacitinib, a Janus kinase 1/3 inhibitor, to not only successfully treat the AA but also maintain her Crohn's disease.
SN - 2326-3253
UR - https://www.unboundmedicine.com/medline/citation/34840997/Treatment_of_Crohn's_Disease_and_Concomitant_Alopecia_Areata_With_Tofacitinib_
DB - PRIME
DP - Unbound Medicine
ER -
Try the Free App:
